Accès ouvert
2026
other
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Fig7. Characterizing peripheral cellular immune environment in patients receiving PGV001. Multicolor flowcytometry performed to phenotype circulating immune cells in patients and healthy donors (HD). PID-017 was excluded from analysis. a) Tabulated view of age and sex of the seven healthy donors …
Accès ouvert
2026
other
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Fig6. Gating strategy for phenotyping of immune cells by flow cytomtery. EM: Effector memory, TEMRA: Effector memory Re-expression RA, CM: Central Memory
Accès ouvert
2026
supplementary-materials
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Table3: List of mutated peptide IDs and peptide sequence in each patients’ vaccine
Accès ouvert
2026
supplementary-materials
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Table2 – Variant count per patient
Accès ouvert
2026
supplementary-materials
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Table1. Staging at time of enrollment, adjuvant treatment following curative intent treatment until the end of vaccination and vaccination timing
Accès ouvert
2026
other
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Fig4. CD4+ and CD8+ T cell activation by PGV001 PBMCs from patients were expanded in vitro in presence of neoantigen peptides (pools of peptides, OLPs+Mins, corresponding to each vaccine SLP) and restimulated with peptide/s followed by intracellular staining and flowcytometry. All …
Accès ouvert
2026
other
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Fig3. Neoantigen specific antibody responses induced by PGV001. Patient plasma was subjected to seromics by ELISA using linear SLPs in the vaccines. N=12 patients. PID-017 excluded from analysis due to high background. a) Stacked bar graph depicting number of neoantigens that …
Accès ouvert
2026
supplementary-materials
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Table5: Cellular Immunophenotyping antibody panels
Accès ouvert
2026
other
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Fig2. PGV001-induced T cell immunity as measured by ex vivo IFNγ ELISPOT assay PBMC samples were stimulated with neoantigen peptides (pools of peptides: composed of 15mer OLPs+ 9-10mer predicted Mins corresponding to each vaccine SLP) and analyzed by IFNγ ELISPOT. All …
Accès ouvert
2026
other
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Fig1. PGV001 feasibility and recurrence free survival a) Survival plot depicting overall survival (OS). N=12. Median survival depicted by vertical dotted line b) Survival plot depicting recurrence free survival (RFS). Median RFS is depicted by vertical dotted line. N=12. c) Swimmer …
Accès ouvert
2026
other
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Fig5. TCR sequencing on neoantigen reactive T cells in patient PBMCs a) (Top) Depiction of methodology utilized to generate ex vivo and in vitro expanded and stimulated (IVS) T cell samples from screen, week 8 (W8) and week 28 (W28) timepoints …
Accès ouvert
2026
supplementary-materials
OpenAlex
Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan et autres
Supplementary Table4: Number of Subjects who had Treatment Emergent Adverse Events by grade, system (13 subjects)